Bijuva is an anti-menopausal drug owned by Therapeuticsmd Inc. It contains active ingredients Estradiol and Progesterone. The drug was first authorized for market use on 28 October 2018.
The generics of Bijuva are expected to be released after 21 November 2032, when the last patent held by Therapeuticsmd Inc. is set to expire.
Bijuva is used for the treatment of menopause symptoms including vasomotor symptoms. The active ingredients, Estradiol and Progesterone, help in reducing these symptoms effectively.
Bijuva currently has 21 active patents, none of which have expired so far. The expiration date for the last patent is 21 November 2032. The patents cover various aspects of the drug including the formulation and therapies. Bijuva generic will become available after that date. Below are the details of the patent: